Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Bayer Launches Phase 3 Prostate Cancer Trial

April 2, 2014 10:35 am | News | Comments

Bayer HealthCare announced that the company has begun to enroll patients in a new Phase 3 trial with radium-223 dichloride (Xofigo) to evaluate radium-223 in combination with abiraterone acetate and prednisone/prednisolone. Read more...    

TOPICS:

EMA App Withdrawn for GSK Ovarian Cancer Drug

April 2, 2014 10:28 am | News | Comments

GlaxoSmithKline announced that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorization for Votrient (pazopanib). Read more...                 

TOPICS:

Janssen Hep C Combo Therapy Moves to Phase 3

April 2, 2014 10:21 am | News | Comments

Janssen R&D Ireland announced that two Phase 3 trials are recruiting patients to examine the efficacy and safety of simeprevir in combination with sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. Read more...

TOPICS:
Advertisement

Merck Serono in Biomarker Collaboration with Pfizer, Broad Institute

April 2, 2014 10:10 am | News | Comments

Merck Serono, the biopharmaceutical division of Merck, announced that its U.S. affiliate EMD Serono has signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Mass.  Read more...            

TOPICS:

GSK Ends Lung Cancer Immunotherapy Trial

April 2, 2014 9:58 am | News | Comments

GlaxoSmithKline announced the company will stop its current trial of MAGE-A3 in non-small cell lung cancer patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. Read more...

TOPICS:

Committee Backs Approval of Cubist Antibiotic for Skin Infection

April 1, 2014 2:34 pm | News | Comments

Cubist Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist’s investigational antibiotic Sivextro (tedizolid phosphate). Read more...

TOPICS:

Court Backs Lilly’s Alimta Patent Until 2022

April 1, 2014 2:25 pm | News | Comments

A federal court has upheld a patent that protects an Eli Lilly lung cancer treatment from cheaper generic competition until 2022. The patent protects a vitamin treatment regimen given before the drug, Alimta, is administered to prevent side effects. Read more...

TOPICS:

Celgene, Forma Announce Multi-Year Strategic Alliance

April 1, 2014 2:13 pm | News | Comments

Forma Therapeutics, an R&D organization in pursuit of medicines in oncology and other therapeutic areas, announced a second strategic collaboration and option agreement with Celgene Corp. Read more...        

TOPICS:
Advertisement

Immunovaccine, Pfenex Post Positive Anthrax Vaccine Results

April 1, 2014 1:58 pm | News | Comments

Immunovaccine Inc. and Pfenex Inc. announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax delivery system. Read more...   

TOPICS:

Janssen Submits NDA for New HIV Combo Drug

April 1, 2014 1:38 pm | News | Comments

Janssen Research & Development LLC announced it has submitted a New Drug Application to the FDA seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor, with cobicistat, an investigational pharmacokinetic enhancer or boosting agent developed for use in combination with other human immunodeficiency virus (HIV-1) medicines. Read more...

TOPICS:

Experimental Cancer Drug Reverses Schizophrenia in Mice

April 1, 2014 1:17 pm | News | Comments

Johns Hopkins researchers say that an experimental anticancer compound appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell function in adolescent mice with a rodent version of the devastating mental illness. Read more...

TOPICS:

Takeda in Licensing Agreement for Trianni Mouse Platform

April 1, 2014 10:47 am | News | Comments

Trianni Inc. and Takeda Pharmaceutical Co. Ltd. jointly announced that they have entered into a license agreement for Takeda’s use of the Trianni Mouse, a monoclonal antibody discovery platform. Read more...             

TOPICS:

Actavis Acquires Thailand's Silom Medical for $100M

April 1, 2014 10:38 am | News | Comments

Drugmaker Actavis Plc plans to expand its reach into Southeast Asia by spending about $100 million to buy Silom Medical Co., a generic pharmaceutical company focused on Thailand. Read more...                 

TOPICS:

Sanofi-Regeneron Cholesterol Drug Excels in Japanese Trial

April 1, 2014 10:24 am | News | Comments

Sanofi and Regeneron announced that the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), in Japanese patients met its primary endpoint. Read more...     

TOPICS:

Bayer Launches Phase 3 Blood Clot Drug Trials

April 1, 2014 9:50 am | News | Comments

Bayer HealthCare and its U.S. development partner Janssen Research & Development LLC announced the initiation of two new Phase 3 trials to evaluate rivaroxaban in medically-ill patients and children at high risk for blood clots. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading